High-dose Wegovy falls short of Zepbound in weight loss trial

A excessive dose of Novo Nordisk’s weight problems drug Wegovy led sufferers to lose substantial weight in a medical trial, however nonetheless lower than what’s been seen with competitor Eli LIlly’s Zepbound.

In a 72-week examine, a 7.2-mg dose of Wegovy led sufferers with weight problems to lose 18.7% of their weight, when taking a look at all members no matter how nicely they adhered to remedy. That in contrast with 15.6% weight reduction amongst individuals taking the presently authorised 2.4-mg dose, and three.9% amongst individuals taking placebo, Novo stated Friday.

Zepbound led to twenty.9% weight reduction over 72 weeks in its pivotal trial.